… stages or stage I only lung adenocarcinomas.28 In the current study, we determined the
clinical relevance of histologic growth patterns in primary lung adenocarcinoma by performing a …

… Further analysis of clinical outcomes demonstrated that the … biomarkers that indicate poor
clinical outcomes (DLD, PDHA1, … with poor clinical outcomes in lung adenocarcinoma, we …

… clinical outcomes between patients with adenocarcinoma … Regarding clinical outcomes,
we demonstrated that anlotinib … in this group of patients with lung cancer. In addition, the …

… The current study analyzed the miRNA expression profiles of 418 lung adenocarcinoma (LUAD)
cases obtained from The Cancer Genome Atlas dataset, with the aim to investigate the …

… 10% of EGFR-mutant lung adenocarcinomas, and are associated with resistance to
EGFR tyrosine kinase inhibitors (TKIs). Clinical outcomes in comparison with patients with …

… Despite these confounders when reporting clinical outcomes, we believe the current series
… in an early-stage LAC population treated with lung SBRT, adding to the literature of mutations …

… These results provide a more complete picture of the pathogenesis of lung … lung
adenocarcinoma for clinical outcome prediction and individualized therapies for lung …

… histomorphologic patterns in lung adenocarcinomas can be used to … risk lung adenocarcinomas
are of high clinical importance in the management of early-stage lung adenocarcinomas. …

… clinically applicable biomarkers associated with the prognosis in as earlier stages as possible.
Clinically, lung … response to available therapies; small cell lung cancer (SCLC) which is …

… expression of two common EGFR mutants seen in human lung cancer. Both transgenic
lines developed lung adenocarcinoma after sustained mutant EGFR expression, with tumour …